Eric Borin Named President of Pharmaceutical Systems Business

FRANKLIN LAKES, N.J., Aug. 24, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Eric Borin to worldwide president, Pharmaceutical Systems, effective today.

In his new role, Borin will have responsibility for driving global strategic, operational and commercial performance across the Pharmaceutical Systems portfolio.

“Eric brings unique capabilities to the leadership role in Pharmaceutical Systems, with a proven track record of customer intimacy, driving change and an innovative and entrepreneurial mindset,” said Alberto Mas, executive vice president and president of the BD Medical Segment. “In addition to his business and commercial impact, Eric is a seasoned leader who empowers high-performing teams focused on driving the right outcomes for our customers and the patients they serve.”

Borin began his career at BD nearly 25 years ago, holding positions of increasing responsibility in multiple businesses and regions across the company, including Pharmaceutical Systems, Medical Surgical Systems, Medical Delivery Solutions and Diabetes Care. Most recently, he served as the vice president and general manager in the Medication Delivery Solutions business, leading simplification of the Infusion Specialty Disposables business and portfolio, as well as launching the business’ next generation Closed System Transfer Device (CSTD) products.

Prior to joining BD, Borin served for five years as an engineer supporting manufacturing, quality, and research and development at a large vaccine manufacturing company.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit  


Jessica Offerjost
BD Public Relations

Anthony Di Meo
BD Investor Relations